Search Results
Dec 17, 2025, 16:05 ET Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy
Linear and Area Coverage with Closed Incision Negative Pressure Therapy Management: International Multidisciplinary Consensus Recommendations. Int Wound J. 2025;22:e7067.3 Cooper HJ, Singh DP, Gabriel A, Mantyh C, Silverman R, Griffin L. Closed Incision Negative Pressure
More news about: Solventum
Dec 12, 2025, 08:12 ET Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
here.ReferencesSmith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143.Servais A, et al. Kidney Int. 2012;82(4):454-464.Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.Tarragón, B, et al. C3 Glomerulopathy Recurs Early after
More news about: Swedish Orphan Biovitrum AB
Dec 12, 2025, 05:00 ET ez1099 2025 Has Been Enhanced with a New Electronic Filing Service!
20252025 Form 1099 Series - including 1099-A, 1099-B, 1099-C,1099-CAP, 1099-D1099-DIV, 1099-G, 1099-INT, 1099-K, 1099-LS, 1099-LTC, 1099-MISC, 1099-NEC, 1099-OID, 1099-PATR, 1099-Q, 1099-QA, 1099-R, 1099-S, 1099-SA, 1099-SB)2025 Form 1098
More news about: Halfpricesoft.com
Dec 11, 2025, 07:47 ET Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
still seek full approval using event free survival as an endpoint.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Dec 09, 2025, 19:26 ET Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
References[1]. J Transl Int Med. 2022;10(2):134-145[2].
More news about: Innovent Biologics
Dec 08, 2025, 14:00 ET Tiger BioSciences Highlights Study on Advanced Placental CAMP Technologies
P.; Guha, S.; Landa, O.; King, A.R.; Valdes Cavazos, D.; Marquez, J.; Hill, S. Native Wound-Repair Proteins Retained in Multilayer Placental CAMPs. Int. J. Mol. Sci. 2025, 26, 10121.
More news about: Tiger BioSciences
Dec 08, 2025, 08:30 ET Primis Financial Corp. Announces Sale-Leaseback Transaction
0.0 %Non-int Income11,969
More news about: Primis Financial Corp.
Dec 05, 2025, 07:30 ET Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
www.intensitytherapeutics.com. About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Dec 04, 2025, 11:00 ET Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
ivJäger R, et al. J Int Soc Sports Nutr. 2017;14:20.v
More news about: Abbott
Dec 04, 2025, 09:00 ET Armada Participates in U.S. Navy UNITAS Exercise, Delivering Power, Data, and Resilience in Disconnected Environments
Edge servers to provide a secure, resilient hybrid cloud environment with enterprise services, as well as Minotaur operator workload, ingesting multi-INT data from multiple robotic autonomous systems (RASs) and other sources. The Galleon also successfully redeployed for ship-based testing with its flexible
More news about: Armada
Dec 04, 2025, 07:47 ET Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Müller, M.D., Swiss Cancer InstituteAbout INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Dec 04, 2025, 02:39 ET The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN
Data on file using literature consensus. Smith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143. Servais A, et al. Kidney Int. 2012;82(4):454-464. Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117. Tarragón, B, et al. C3 Glomerulopathy Recurs Early
More news about: Swedish Orphan Biovitrum AB
Dec 03, 2025, 18:10 ET Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Dec 02, 2025, 16:40 ET New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Horie et al., CSF MTBR-tau243 is a specific biomarker
More news about: Eisai Inc.
Nov 28, 2025, 20:00 ET SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
nodes.The mission supports broader international efforts to establish quantum-secure communication networks, including the European Space Agency's INT-UQKD and Q-DESIGN programmes, highlighting global recognition of quantum communications as critical technology for future cybersecurity.Singapore-UK
More news about: SpeQtral
Nov 25, 2025, 07:30 ET Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway
More news about: Eisai Inc.
Nov 21, 2025, 04:00 ET ez1099 2025 Launches, Making Tax Season Effortless for Accountants and SMBs
users."Built for efficiency and accuracy, ez1099 offers:Easy setup and form preparation for 1099-MISC, 1099-NEC, 1099-INT, 1099-DIV, 1098, and moreThe ability to print forms on plain white paper—no red ink forms requiredSecure import, data review, and e-filing
More news about: Halfpricesoft.com
Nov 18, 2025, 08:00 ET Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
10.1038/s41467-021-23507-z.2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Nov 17, 2025, 11:19 ET BGN Announces Strategic MOU with XCF Global to produce and supply Sustainable Aviation Fuel
HOUSTON, Nov. 17, 2025 /PRNewswire/ -- BGN INT US LLC ("BGN"), an independent global energy and commodities group and a market leader in transition fuels has signed a Memorandum of Understanding
More news about: BGN
Nov 14, 2025, 08:37 ET Samson Clinical Announces Completion of Patient Enrolment into Pivotal Phase III Clinical Trial Program for Sublingual Minoxidil in Male Pattern Baldness
1. Sinclair, R. D., Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol, 2018; 57: 104–109. doi:10.1111/ijd.13838. 2. Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A,
More news about: Samson Clinical Operations Pty Ltd
Nov 14, 2025, 07:00 ET Version 2025 ez1099 Tax Preparation Software Seamlessly Supports Data Transfer from Year to Year
e-filing these other IRS forms: W2G, 1099-OID, 1097BTC, 1098s (1098, 1098C, 1098E, 1098 T), 1099s (1099A, 1099B, 1099C, 1099CAP, 1099DIV, 1099G, 1099H, 1099INT, 1099LTC, 1099MISC, 1099OID, 1099PATR, 1099Q, 1099R, 1099S, 1099SA), 5498s (5498, 5498ESA, 5498SA), 8935, 3921, 3922, 1096 1098-F form, and 1099-NEC
More news about: Halfpricesoft.com
Nov 13, 2025, 06:13 ET MolecuLight to Exhibit and Showcase New Consensus on Fluorescence Imaging in Surgical Wound Management at IPAWS Summit 2025
Davenport T, Tettlebach W, Bohn G, Lantis JC, Suski M, Low M, Desvigne MN. Fluorescence imaging in surgical wound management: a consensus-based approach. Int J Tissue Repair. 2025;1(1):2–9. doi:10.63676/pxws0177 About MolecuLight Corp. and its wound imaging
More news about: MolecuLight Corp.
Nov 12, 2025, 14:33 ET Wspólny dobrobyt w erze inteligencji: Forum China International Intelligent Communication 2025 odbyło się w Wuxi
wykładowca Chińskiej Akademii Nauk (CAS); Dmitry Palchunov, wykładowca Rosyjskiej Akademii Inżynierii i międzynarodowy współprzewodniczący Solvable Lab INT.; Guo Tong, prezes CCTV.com oraz prezes i dyrektor generalny Yangshipin.cn; Churchill Otieno, przewodniczący African Editors Forum; Tong Jisheng, przewodniczący
More news about: CCTV.com
Nov 12, 2025, 10:23 ET New Survey Reveals Critical Gaps in Awareness and Understanding of Agitation in Alzheimer's Dementia
J, Tong J, Hartry A, Olaoye A, Aigbogun MS. Using electronic health records to estimate the prevalence of agitation in Alzheimer's disease/dementia. Int J Geriatr Psychiatry. 2019;34(3):420-431. Senanarong V, Cummings JL, Fairbanks L, et al. Agitation in Alzheimer's disease
More news about: Alliance for Aging Research
Nov 11, 2025, 06:56 ET Foro Internacional de Comunicación Inteligente de China 2025 celebrado en Wuxi
académico de la Academia China de Ciencias (CAS); Dmitry Palchunov, académico de la Academia Rusa de Ingeniería, copresidente internacional de Solvable Lab INT.; Guo Tong, presidente de CCTV.com, presidente y director general de Yangshipin.cn; Churchill Otieno, presidente del Foro de Editores Africanos; Tong
More news about: CCTV.com